.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
McKinsey
Chinese Patent Office
Cipla
Fish and Richardson
Moodys
Argus Health
Accenture
Chubb
Boehringer Ingelheim

Generated: September 26, 2017

DrugPatentWatch Database Preview

Wyeth Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for WYETH PHARMS INC, and what generic alternatives to WYETH PHARMS INC drugs are available?

WYETH PHARMS INC has thirty-one approved drugs.

There are eighteen US patents protecting WYETH PHARMS INC drugs on WYETH PHARMS INC drugs in the past three years.

There are three hundred and ten patent family members on WYETH PHARMS INC drugs in sixty-four countries.

Summary for Applicant: Wyeth Pharms Inc

Patents:18
Tradenames:29
Ingredients:19
NDAs:31
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Inc
ORUVAIL
ketoprofen
CAPSULE, EXTENDED RELEASE;ORAL019816-001Sep 24, 1993DISCNYesNo► Subscribe► Subscribe► Subscribe
Wyeth Pharms Inc
PROTONIX
pantoprazole sodium
TABLET, DELAYED RELEASE;ORAL020987-001Feb 2, 2000ABRXYesYes► Subscribe► SubscribeY► Subscribe
Wyeth Pharms Inc
ZOSYN IN PLASTIC CONTAINER
piperacillin sodium; tazobactam sodium
INJECTABLE;INJECTION050750-003Feb 24, 1998RXYesYes► Subscribe► SubscribeY ► Subscribe
Wyeth Pharms Inc
ZOSYN
piperacillin sodium; tazobactam sodium
INJECTABLE;INJECTION050684-003Oct 22, 1993APRXYesYes► Subscribe► SubscribeY ► Subscribe
Wyeth Pharms Inc
ZOSYN
piperacillin sodium; tazobactam sodium
INJECTABLE;INJECTION050684-001Oct 22, 1993APRXYesYes► Subscribe► SubscribeY ► Subscribe
Wyeth Pharms Inc
NORPLANT SYSTEM IN PLASTIC CONTAINER
levonorgestrel
IMPLANT;IMPLANTATION020088-001Dec 10, 1990DISCNNoNo► Subscribe► Subscribe► Subscribe
Wyeth Pharms Inc
ZOSYN IN PLASTIC CONTAINER
piperacillin sodium; tazobactam sodium
INJECTABLE;INJECTION050750-001Feb 24, 1998RXYesYes► Subscribe► SubscribeY ► Subscribe
Wyeth Pharms Inc
PRISTIQ
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL021992-003Aug 20, 2014ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Wyeth Pharms Inc
EFFEXOR
venlafaxine hydrochloride
TABLET;ORAL020151-006Dec 28, 1993DISCNYesNo► Subscribe► Subscribe► Subscribe
Wyeth Pharms Inc
QUINIDEX
quinidine sulfate
TABLET, EXTENDED RELEASE;ORAL012796-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Wyeth Pharms Inc

Paragraph IV activity for WYETH PHARMS INC drugs

Drugname Dosage Strength Tradename Submissiondate
desvenlafaxine succinate
Extended-release Tablets 25 mg
PRISTIQ
5/8/2015
desvenlafaxine succinate
Extended-release Tablets50 mg and 100 mg
PRISTIQ
2/29/2012
piperacillin sodium and tazobactam sodium
For Injection12 g/1.5 g per vial (pharmacy bulk)
ZOSYN
12/6/2011
levonorgestrel and ethinyl estradiol
Tablets0.09 mg/0.02 mg
LYBREL
10/5/2007
venlafaxine hydrochloride
Extended-release Tablets37.5 mg, 75 mg and 150 mg
EFFEXOR XR
5/3/2007
venlafaxine hydrochloride
Tablets25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg
EFFEXOR
11/3/2005
pantoprazole sodium
Delayed-release Tablets20 mg and 40 mg
PROTONIX
2/2/2004

Non-Orange Book Patents for Wyeth Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,026,508Succinate salt of O-desmethyl-venlafaxine► Subscribe
7,498,312Compositions containing piperacillin and tazobactam useful for injection► Subscribe
7,291,347Succinate salt of O-desmethyl-venlafaxine► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Wyeth Pharms Inc Drugs

Country Document Number Estimated Expiration
South Korea100910607► Subscribe
Canada2109697► Subscribe
China1476335► Subscribe
Peru57198► Subscribe
Norway332937► Subscribe
China1090018► Subscribe
Austria381946► Subscribe
Portugal1360169► Subscribe
Australia1640097► Subscribe
Argentina014012► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Wyeth Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB02/037United Kingdom► SubscribePRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
C0001France► SubscribePRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
C/GB99/008United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
2009 00017Denmark► SubscribePRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629
00221Netherlands► SubscribePRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
13/055Ireland► SubscribePRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624
00C/027Belgium► SubscribePRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
2016 00016Denmark► SubscribePRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
C0062France► SubscribePRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626
1214076/01Switzerland► SubscribePRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Farmers Insurance
Julphar
Colorcon
Deloitte
Medtronic
Chinese Patent Office
UBS
QuintilesIMS
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot